Surgical management of dermatofibrosarcoma protuberans.
Mohs micrographic surgery
dermatofibrosarcoma protuberans
sarcoma
surgery
wide local excision
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
08
02
2023
received:
17
10
2022
accepted:
09
03
2023
medline:
13
6
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive cutaneous malignancy. Complete resection is the primary treatment but there is debate over the optimal method. Wide local excision was traditionally the standard of care; however, National Comprehensive Cancer Network guidelines now recommend Mohs micrographic surgery as the preferred approach. Medical therapy with imatinib can be used in advanced or unresectable disease. This review will discuss the current management of DFSP, focusing on optimal surgical approach.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-96Subventions
Organisme : NIH/NCI Grant
ID : 1R01 CA158301
Organisme : Herbert Irving Cancer Support Grant
ID : P30CA013696
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(suppl 1):S24-S31.
Rouhani P, Fletcher CDM, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616-627.
Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600-613.
Martin L, Piette F, Blanc P, et al. Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol. 2005;153:932-936.
Bowne WB, Antonescu CR, Leung DHY, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711-2720.
Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669-7675.
Hao X, Billings SD, Wu F, et al. Dermatofibrosarcoma protuberans: update on the diagnosis and treatment. J Clin Med. 2020;9:1752.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Dermatofibrosarcoma Protuberans Version 2.2022, 2022.
Walluks K, Chen Y, Woelfel C, et al. Molecular and clinicopathological analysis of dermatofibrosarcoma protuberans. Pathol Res Pract. 2013;209:30-35.
Laskin WB. Dermatofibrosarcoma protuberans. CA Cancer J Clin. 1992;42:116-125.
Llombart B, Monteagudo C, Sanmartín O, et al. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol. 2011;65:564-575.
Thway K, Noujaim J, Jones RL, Fisher C. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol. 2016;25:64-71.
Liang CA, Jambusaria-Pahlajani A, Karia PS, Elenitsas R, Zhang PD, Schmults CD. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71:781-786.
Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576-587.
Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol. 2000;24:1125-1130.
Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosom Cancer. 2003;37:1-19.
Shimizu A, O'brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59:3719-3723.
Takahira T, Oda Y, Tamiya S, et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol. 2007;20:668-675.
Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436-443.
Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol. 2011;18:328-336.
Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341-345.
Heuvel ST, Suurmeijer A, Pras E, Van Ginkel RJ, Hoekstra HJ. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol. 2010;36:89-94.
Kim BJ, Kim H, Jin US, Minn KW, Chang H. Wide local excision for dermatofibrosarcoma protuberans: a single-center series of 90 patients. BioMed Res Int. 2015;2015:1-9.
DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008-1016.
Popov P, Böhling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for dermatofibrosarcoma protuberans. Plast Reconstr Surg. 2007;119:1779-1784.
Behbahani R, Patenotre P, Capon N, et al. Vers une réduction des marges latérales dans les dermatofibrosarcomes de darier et ferrand? étude rétrospective de 34 cas. Ann Chir Plast Esthét. 2005;50:179-185.
Monnier D, Vidal C, Martin L, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol. 2006;20:1237-1242.
Cai H, Wang Y, Wu J, Shi Y. Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol. 2012;105:142-148.
Woo KJ, Bang SI, Mun GH, Oh KS, Pyon JK, Lim SY. Long-term outcomes of surgical treatment for dermatofibrosarcoma protuberans according to width of gross resection margin. J Plastic Reconstruct Aesthet Surg. 2016;69:395-401.
Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol. 2010;17:2112-2118.
Huether MJ, Zitelli JA, Brodland DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol. 2001;44:656-659.
Loghdey MS, Varma S, Rajpara SM, Al-Rawi H, Perks G, Perkins W. Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): a single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. J Plastic Reconstruct Aesthet Surg. 2014;67:1315-1321.
Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev. 2008;34:728-736.
Meguerditchian AN, Wang J, Lema B, Kraybill WG, Zeitouni NC, Kane JM. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol. 2010;33:300-303.
Lowe GC, Onajin O, Baum CL, et al. A comparison of Mohs micrographic surgery and wide local excision for treatment of dermatofibrosarcoma protuberans with long-term follow-up: the Mayo Clinic experience. Dermatol Surg. 2017;43:98-106.
Durack A, Gran S, Gardiner MD, et al. A 10-year review of surgical management of dermatofibrosarcoma protuberans. Br J Dermatol. 2021;184:731-739.
Massey RA, Tok J, Strippoli BA, Szabolcs MJ, Silvers DN, Eliezrl YD. A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans. Dermatol Surg. 1998;24:995-998.
Tom WD, Hybarger CP, Rasgon BM. Dermatofibrosarcoma protuberans of the head and neck: treatment with Mohs surgery using inverted horizontal paraffin sections. Laryngoscope. 2003;113:1289-1293.
Tan WP, Barlow RJ, Robson A, Kurwa HA, McKenna J, Mallipeddi R. Dermatofibrosarcoma protuberans: 35 patients treated with Mohs micrographic surgery using paraffin sections. Br J Dermatol. 2011;164:363-366.
Chaput B, Filleron T, Le Guellec S, et al. Dermatofibrosarcoma protuberans: margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients. Ann Chir Plast Esthét. 2014;59:219-225.
Asilian A, Honarjou N, Faghihi G, Saber M, Mozafarpoor S, Hafezi H. An experience of slow-Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: a long-term cohort study. J Cosmet Dermatol. 2020;19:2701-2705.
Nieto-Benito LM, Ciudad-Blanco C, Sanmartin-Jimenez O, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. Exp Dermatol. 2021;30:717-722.
Foroozan M, Sei JF, Amini M, Beauchet A, Saiag P. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148:1055-1063.
Martin ECS, Vyas KS, Batbold S, Erwin PJ, Brewer JD. Dermatofibrosarcoma protuberans recurrence after wide local excision versus mohs micrographic surgery: a systematic review and meta-analysis. Dermatol Surg. 2022;48:479-485.
Saiag P, Grob JJ, Lebbe C, et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:2604-2608.
Udkoff J, Russell E, Beal BT, et al. Cost effectiveness of dermatofibrosarcoma protuberans treated with Mohs micrographic surgery compared with wide local excision. J Am Acad Dermatol. 2022;87:1156-1157.
Mullen JT. Dermatofibrosarcoma protuberans. Surg Oncol Clin N Am. 2016;25:827-839.
Chappell AG, Doe SC, Worley B, et al. Multidisciplinary surgical treatment approach for dermatofibrosarcoma protuberans: an update. Arch Dermatol Res. 2021;313:367-372.
Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.
Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol. 2019;155:361-369.
Rutkowski P, Klimczak A, Ługowska I, et al. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate-the impact of fibrosarcomatous transformation. Eur J Surg Oncol. 2017;43:1134-1141.
Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:585-590.
Du K, Li J, Tang L, et al. Role of postoperative radiotherapy in dermatofibrosarcoma protuberans: a propensity score-matched analysis. Radiat Oncol. 2019;14:20.
Williams N, Morris CG, Kirwan JM, Dagan R, Mendenhall WM. Radiotherapy for dermatofibrosarcoma protuberans. Am J Clin Oncol. 2014;37:430-432.
Huis In ‘t Veld EA, van Coevorden F, Grünhagen DJ, et al. Outcome after surgical treatment of dermatofibrosarcoma protuberans: is clinical follow-up always indicated? Cancer. 2019;125:735-741.